Roche Vitamins, Inc. v. United States , 772 F.3d 728 ( 2014 )


Menu:
  •   United States Court of Appeals
    for the Federal Circuit
    ______________________
    ROCHE VITAMINS, INC.,
    Plaintiff-Appellee,
    v.
    UNITED STATES,
    Defendant-Appellant.
    ______________________
    2013-1568
    ______________________
    Appeal from the United States Court of International
    Trade in No. 04-CV-0175, Judge Richard K. Eaton.
    ______________________
    Decided: November 20, 2014
    ______________________
    ERIK D. SMITHWEISS, Grunfeld, Desiderio, Lebowitz,
    Silverman & Klestadt LLP, of New York, New York,
    argued for plaintiff-appellee. With him on the brief were
    ROBERT B. SILVERMAN and JOSEPH M. SPRARAGEN.
    PATRICIA M. MCCARTHY, Assistant Director, Commer-
    cial Litigation Branch, Civil Division, United States
    Department of Justice, of Washington, DC, argued for
    defendant-appellant. With her on the brief were STUART
    F. DELERY, Assistant Attorney General, and JEANNE E.
    DAVIDSON, Director. Of counsel on the brief were EDWARD
    N. MAURER and SHERYL A. FRENCH, Office of Assistant
    Chief Counsel, International Trade Litigation, United
    2                                ROCHE VITAMINS, INC.   v. US
    States Customs & Border Protection, of New York, New
    York. Of counsel was SAUL DAVIS, Attorney, Appellate
    Section, International Trade Litigation, International
    Trade Field Office, United States Department of Justice,
    of New York, New York.
    ______________________
    Before PROST, Chief Judge, LOURIE and DYK, Circuit
    Judges.
    LOURIE, Circuit Judge.
    The United States (“the government”) appeals from
    the decision of the United States Court of International
    Trade reclassifying Roche Vitamin Inc.’s (“Roche”) product
    BetaTab 20% (“BetaTab”) as “Provitamins, unmixed”
    under subheading 2936.10.00 of the Harmonized Tariff
    Schedule of the United States (“HTSUS”). See Roche
    Vitamins, Inc. v. United States, 
    922 F. Supp. 2d 1353
     (Ct.
    Int’l Trade 2013) (“Opinion”). Because the Court of Inter-
    national Trade correctly classified BetaTab under heading
    2936, we affirm.
    BACKGROUND
    Roche imported BetaTab, which is a mixture contain-
    ing beta-carotene, antioxidants, gelatin, sucrose, and corn
    starch, and can be used as a source of Vitamin A in foods,
    beverages, and vitamin products. Beta-carotene crystal-
    line makes up twenty percent of the mixture and is an
    organic colorant with provitamin A activity. Whether
    used as a colorant or provitamin A, beta-carotene must
    first be combined with other ingredients.
    The United States Customs and Border Protection
    (“Customs”) classified BetaTab under HTSUS subheading
    2106.90.97 as “[f]ood preparations not elsewhere specified
    or included.” 
    Id. at 1356
    . Roche filed a protest to the
    liquidation of BetaTab, which Customs denied. 
    Id.
     Roche
    ROCHE VITAMINS, INC.   v. US                             3
    then filed suit in the Court of International Trade and
    moved for summary judgment.
    Roche argued that BetaTab was classifiable either as
    a “coloring matter” under HTSUS subheading 3204.19.35,
    and eligible for duty-free entry pursuant to the Pharma-
    ceutical Appendix, or, alternatively, as a provitamin
    under HTSUS heading 2936. The Court of International
    Trade denied Roche’s motion for summary judgment.
    Roche Vitamins, Inc. v. United States, 
    750 F. Supp. 2d 1367
    , 1382 (Ct. Int’l Trade 2010). The court concluded
    that genuine issues of material fact as to the principal use
    of BetaTab and the functionality of BetaTab’s ingredients
    other than beta-carotene precluded summary judgment.
    
    Id.
    Following trial, the Court of International Trade first
    determined that the principal use of BetaTab was as a
    source of provitamin A in foods or vitamin products,
    rather than as a coloring matter. Opinion at 1360. As
    part of the principal use analysis, the court found that
    “BetaTab was developed for use in vitamin products and
    its actual use during the relevant time period was pre-
    dominantly as a source of Provitamin A for vitamin
    products.” 
    Id.
     The court explained that the “high concen-
    tration and high bioavailability of beta-carotene in the
    merchandise [made] it preferable for use in dietary sup-
    plement tablets.” Id. at 1361. The court also noted that
    BetaTab was developed specifically “for use in high poten-
    cy and anti-oxidative vitamin tablets.” Id.
    The court then considered whether BetaTab was
    properly classified under HTSUS heading 2936 as a
    provitamin. Citing Note 1 to Chapter 29 and the Explan-
    atory Notes to Chapter 29, the court explained that a
    product would not properly be classified under heading
    2936 “if the quantity of a stabilizing agent added to an
    item of [heading 2936] is more than is necessary for
    transport or preservation, or the nature of the stabilizing
    4                                 ROCHE VITAMINS, INC.   v. US
    agent alters the character of the basic product so as to
    render it ‘particularly suitable for specific use.’” Id. at
    1358–59. The court noted that “[a]dded ingredients that
    make a chemical highly capable of a use that is not an
    ordinary use of chemicals of the heading . . . will render
    the item ‘particularly suitable for specific use rather than
    for general use’ and exclude it from classification in the
    headings of Chapter 29.” Id. at 1359 (emphasis in origi-
    nal).
    Based on the evidence presented at trial, the court
    found that a stabilizing matrix of some kind is necessary
    for any beta-carotene product, and beta-carotene must be
    processed and combined with other ingredients to be
    commercially useable as either a provitamin A or color-
    ant. Id. at 1362. The court found that Roche’s manufac-
    turing process did not change BetaTab’s functionality as a
    provitamin or change the character of beta-carotene as a
    source of provitamin A. Id. According to the court, there
    was “no evidence that the merchandise’s non-beta-
    carotene ingredients enhance absorption or bioavailablity
    of the beta-carotene in a manner greater than any other
    stabilizing matrix.” Id. The court found that although
    BetaTab was highly suitable for tableting, BetaTab itself
    contained no ingredients “specifically prepared for tablet-
    ing.” Id. The court noted that the stabilizers used in
    BetaTab were essentially the same as those used to
    stabilize other vitamins and other beta-carotene products
    that are marketed for use as colorants. Id.
    The court concluded that “[i]t was demonstrated as a
    matter of fact at trial that BetaTab’s additional non-beta-
    carotene ingredients, added as stabilizers, do not make
    [BetaTab] particularly suitable for a specific use.” Id. at
    1363. As a result, the court concluded that the addition of
    the stabilizing ingredients was permissible under Note 1
    to Chapter 29, and did not exclude the merchandise from
    classification under heading 2936. Id. at 1364. The court
    concluded that, because BetaTab was “elsewhere includ-
    ROCHE VITAMINS, INC.   v. US                             5
    ed,” Customs’ classification under heading 2106 was
    incorrect and BetaTab was properly classified under 2936.
    Id. The court then reasoned that because BetaTab is a
    provitamin compound, BetaTab was properly classified
    further under subheading 2936.10.00. Id. at 1365.
    The government timely appealed. We have jurisdic-
    tion pursuant to 
    28 U.S.C. § 1295
    (a)(5).
    DISCUSSION
    We review questions of law de novo, including the
    interpretation of HTSUS terms. Home Depot U.S.A., Inc.
    v. United States, 
    491 F.3d 1334
    , 1335 (Fed Cir. 2007).
    The determination of whether a particular product fits
    within that interpretation is a question of fact, reviewable
    for clear error. Nat’l Advanced Sys. v. United States, 
    26 F.3d 1107
    , 1109 (Fed. Cir. 1994).
    Merchandise imported into the United States is clas-
    sified under the HTSUS. The HTSUS scheme is orga-
    nized by headings, each of which has one or more
    subheadings; the headings set forth general categories of
    merchandise, and the subheadings provide a more partic-
    ularized segregation of the goods within each category.
    The classification of merchandise under the HTSUS is
    governed by the principles set forth in the General Rules
    of Interpretation (“GRIs”) and the Additional U.S. Rules
    of Interpretation. See Orlando Food Corp. v. United
    States, 
    140 F.3d 1437
    , 1439 (Fed. Cir. 1998). GRI 1
    provides that “for legal purposes, classification shall be
    determined according to the terms of the headings and
    any relative Section or Chapter Notes and, provided such
    headings or Notes do not otherwise require, according to
    the [remaining GRIs.]” GRI 1. The Chapter Notes are an
    integral part of the HTSUS, and have the same legal force
    as the text of the headings. Degussa Corp. v. United
    States, 
    508 F.3d 1044
    , 1047 (Fed. Cir. 2007).
    The relevant section of the HTSUS reads as follows:
    6                                  ROCHE VITAMINS, INC.   v. US
    2936 Provitamins and vitamins, natural or re-
    produced by synthesis (including natural concen-
    trates), derivatives thereof used primarily as
    vitamins, and intermixtures of the foregoing,
    whether or not in any solvent:
    2936.10      Provitamins, unmixed
    Heading 2936, HTSUS (2002).
    HTSUS Note 1 to Chapter 29 provides: “Except where
    the context otherwise requires, the headings of this Chap-
    ter apply only to: . . . (f) The products mentioned in (a),
    (b), (c), (d) or (e) above with an added stabilizer (including
    an anticaking agent) necessary for their preservation or
    transport.” HTSUS Ch. 29, n.1 (2002) (emphases added).
    The Explanatory Notes for HTSUS Chapter 29 pro-
    vide further insight as to the proper classification of
    merchandise under heading 2936. Explanatory Notes are
    not legally binding, but may be consulted for guidance
    and are generally indicative of the proper interpretation
    of a tariff provision. Motorola, Inc. v. United States, 
    436 F.3d 1357
    , 1361 (Fed. Cir. 2006). Explanatory Note 29.36
    states:
    This heading includes: . . .
    (a) Provitamins and vitamins, whether natural or
    reproduced by synthesis, and derivatives thereof
    used primarily as vitamins. . . .
    (d) The above products diluted in any solvent (e.g.,
    ethyl oleate, propane-1,2-diol, ethanediol, vege-
    table oils).
    The products of this heading may be stabilised
    for the purposes of preservation or transport:
    - by adding anti-oxidants,
    - by adding anti-caking agents (e.g. carbohy-
    drates),
    ROCHE VITAMINS, INC.   v. US                                7
    - by coating with appropriate substances (e.g.
    gelatin, waxes or fats), whether or not plasti-
    cized, or
    - by adsorbing on appropriate substances (e.g., si-
    licic acid),
    provided that the quantity added or the processing
    in no case exceeds that necessary for their preser-
    vation or transport and that the addition or pro-
    cessing does not alter the character of the basic
    product and render it particularly suitable for spe-
    cific use rather than for general use.
    Explanatory Notes to the Harmonized Commodity
    Description and Coding System 29.36 (3d ed. 2002)
    (emphasis added) (“Explanatory Notes”); J.A. 336.
    The government argues that heading 2936 excludes
    products that have undergone processing that renders
    them suitable for a specific use, and BetaTab is processed
    to such a degree that it has been rendered particularly
    suitable for use as a nutritional ingredient in vitamin
    tablets and capsules. The government contends that
    nothing in either the text or the Explanatory Notes to
    Chapter 29 supports the Court of International Trade’s
    new interpretation that a “specific use” disqualifying
    classification under Chapter 29 must necessarily be “a use
    that is not an ordinary use of chemicals of the heading.”
    E.g., Appellant’s Br. 10.
    Roche responds that BetaTab is properly classified as
    a provitamin under heading 2936 and it satisfies the
    limitations of Note 1 to Chapter 29 and Explanatory Note
    29.36. Roche argues that BetaTab contains no ingredi-
    ents that specifically prepare it for use in tablets, and the
    evidence at trial demonstrated that BetaTab is suitable
    for general use, i.e., for use in tablets, capsules, foods, and
    even as a colorant. Roche contends that the added stabi-
    lizing agents do not render BetaTab particularly suitable
    8                                 ROCHE VITAMINS, INC.   v. US
    for a specific use rather than for general use, and BetaTab
    must first be combined with tableting excipients to be
    formed into a tablet.
    We agree with Roche that BetaTab is properly classi-
    fied as a provitamin under heading 2936 because it fulfills
    the description in the statutory heading and satisfies the
    limitations of both Note 1 to Chapter 29 and Explanatory
    Note 29.36. It is a stipulated fact that beta-carotene has
    provitamin A activity, J.A. 84, and there is no dispute
    regarding the Court of International Trade’s finding that
    BetaTab is accurately described as a provitamin of head-
    ing 2936, subject to the limitations of Note 1 to Chapter
    29 and Explanatory Note 29.36. Thus, because in this
    case no interpretation of HTSUS terms is before us, we
    review the conclusions of the Court of International Trade
    for clear error.
    Note 1(f) to Chapter 29 permits the addition of stabi-
    lizer ingredients to BetaTab, as long as the amount of
    stabilizer added is not more than necessary for preserva-
    tion or transport. In its denial of summary judgment, the
    Court of International Trade held that “the stabilizing
    ingredients . . . are not in quantities greater than neces-
    sary to achieve stabilization.” Roche, 
    750 F. Supp. 2d at
    1381 n.11. The parties did not dispute this point at trial,
    Opinion at 1359 n.5, and the government acknowledged
    during oral argument that it is not raising the argument
    now on appeal, Oral Argument at 7:41, Roche Vitamins,
    Inc. v. United States, No. 2013-1568, available at
    http://www.cafc.uscourts.gov/oral-argument-recordings/all
    /roche-vitamins.html. Thus, we do not need to address
    this point.
    Explanatory Note 29.36 expands on Note 1(f) to Chap-
    ter 29 and permits the addition of stabilizer ingredients if
    the addition or processing does not (1) alter the character
    of the basic product and (2) render it particularly suitable
    for specific use rather than for general use. The govern-
    ROCHE VITAMINS, INC.   v. US                             9
    ment’s expert testified, and the Court of International
    Trade found, that Roche’s manufacturing process does not
    change BetaTab’s functionality as provitamin A or change
    the character of the beta-carotene as provitamin A. J.A.
    307; Opinion at 1362. The government does not provide
    any evidence to the contrary. We therefore conclude that
    the Court of International Trade did not clearly err in
    finding that the additional ingredients and processing do
    not alter the character of the beta-carotene.
    Nor does the addition of stabilizer ingredients render
    the basic product, beta-carotene, particularly suitable for
    specific use rather than for general use. Expert testimony
    established that the sucrose and gelatin additives func-
    tion as stabilizers and do not “specifically prepare
    [BetaTab] for tableting.” J.A. 165. In addition, the record
    demonstrates that BetaTab has no ingredients added
    specifically for tableting, such as tableting excipients.
    J.A. 164, 165. The stabilizers used in BetaTab were
    essentially the same as those used to stabilize other
    vitamins and other beta-carotene products that were
    marketed for use as colorants. J.A. 134, 137, 144, 213;
    Opinion at 1362. Although the high concentration and
    high bioavailability of beta-carotene in BetaTab make it
    preferable for use for the manufacture of tablets, no
    evidence supports the assertion that the added stabilizers
    make BetaTab particularly suitable for tableting. As a
    result, the Court of International Trade did not clearly err
    in finding that the addition of stabilizer ingredients did
    not render BetaTab particularly suitable for the specific
    use of tableting.
    Notably, BetaTab also remains suitable for general
    use. Expert testimony established that BetaTab is “well-
    suited for fortifying foods with provitamin A,” J.A. 235,
    and “is suitable for general use as provitamin A,” J.A.
    307. BetaTab can thus be used as a source of vitamin A
    in foods, beverages, and vitamin products. Consequently,
    10                                ROCHE VITAMINS, INC.   v. US
    the Court of International Trade did not clearly err in
    finding that BetaTab remains suitable for general use.
    The government places significant emphasis on the
    Court of International Trade’s conclusion that “[a]dded
    ingredients that make a chemical highly capable of a use
    that is not an ordinary use of chemicals of the heading . . .
    will render the item ‘particularly suitable for specific use
    rather than for general use.’” E.g., Appellant’s Br. 10.
    Although the court appears to have erred in this overly-
    narrow interpretation of Explanatory Note 29.36, the
    record demonstrates that the addition of stabilizer ingre-
    dients did not render BetaTab particularly suitable for
    specific use rather than for general use. Thus, the court
    did not clearly err in classifying BetaTab as a provitamin
    under heading 2936.
    Customs classified BetaTab under heading 2106,
    which covers “[f]ood preparations not elsewhere specified.”
    Opinion at 1356 (emphasis added). Because BetaTab is
    properly classified under 2936, Customs’ classification
    under heading 2106 cannot stand because BetaTab is
    elsewhere specified. Assuming that BetaTab is properly
    classified under heading 2936, the government does not
    dispute that BetaTab is properly further classified as
    “Provitamins, unmixed” under subheading 2936.10.00.
    CONCLUSION
    Because the addition of stabilizer ingredients does not
    render BetaTab particularly suitable for specific use
    rather than for general use, we conclude that the Court of
    International Trade did not err in classifying BetaTab as
    “Provitamins, unmixed” under subheading 2936.10.00.
    Accordingly, the judgment of the Court of International
    Trade is affirmed.
    AFFIRMED
    

Document Info

Docket Number: 2013-1568

Citation Numbers: 772 F.3d 728, 36 I.T.R.D. (BNA) 972, 2014 U.S. App. LEXIS 21963, 2014 WL 6480519

Judges: Prost, Lourie, Dyk

Filed Date: 11/20/2014

Precedential Status: Precedential

Modified Date: 10/19/2024